✦ LIBER ✦

Bevacizumab-containing chemotherapy for non-small cell lung cancer patients: a population-based observational study by the Ibaraki thoracic integrative (POSITIVE) research group

✍ Scribed by Hiroyuki Nakamura, Hiroaki Satoh, Takayuki Kaburagi, Yoshihiro Nishimura, Yoko Shinohara, Masaharu Inagaki, Takeo Endo, Takefumi Saito, Kenji Hayashihara, Nobuyuki Hizawa, Koichi Kurishima, Takeshi Nawa, Katsunori Kagohashi, Koji Kishi, Hiroichi Ishikawa, et al

Book ID: 118821702
Publisher: Springer US
Year: 2012
Tongue: English
Weight: 190 KB
Volume: 29
Category: Article
ISSN: 1357-0560
DOI: 10.1007/s12032-012-0318-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Docetaxel plus cisplatin and bevacizumab

Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group

✍ N. Kentepozidis, A. Kotsakis, A. Soultati… 📂 Article 📅 2013 🏛 Springer 🌐 English ⚖ 214 KB

Combination chemotherapy of gemcitabine

Combination chemotherapy of gemcitabine and vinorelbine for patients in stage IIIB–IV non-small cell lung cancer: a phase II study of the West Japan Thoracic Oncology Group (WJTOG) 9908

✍ Katakami, Nobuyuki; Sugiura, Takahiko; Nogami, Toshiji; Yamamoto, Hidehiko; Nego 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 130 KB

Treatment Rationale and Study Design for

Treatment Rationale and Study Design for the PointBreak Study: A Randomized, Open-label Phase III Study of Pemetrexed/Carboplatin/Bevacizumab Followed by Maintenance Pemetrexed/Bevacizumab Versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer

✍ Jyoti D. Patel; Philip Bonomi; Mark A. Socinski; Ramaswamy Govindan; Shengyan Ho 📂 Article 📅 2009 🏛 CIG Media Group, LP. 🌐 English ⚖ 100 KB

6570 POSTER Results for progression-free

6570 POSTER Results for progression-free survival (PFS) from two randomised, double-blind, multicentre phase III studies of bevacizumab in combination with platin-based chemotherapy in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) are comparable when analysed by similar populations and methodology

✍ Sandler, A.; Reck, M.; vonPawel, J.; Zatloukal, P.; Ramlau, R.; Gorbounova, V.; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 58 KB

Rapidly alternating combination of cispl

Rapidly alternating combination of cisplatin-based chemotherapy and hyperfractionated accelerated radiotherapy in split course for stage IIIA and stage IIIB non-small cell lung cancer: Results of a phase I–II study by the GOTHA group

📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 131 KB

Treatment Rationale Study Design for the

Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non–Small-Cell Lung Cancer

✍ David R. Spigel; Martin J. Edelman; Tony Mok; Kenneth O'Byrne; Luis Paz-Ares; We 📂 Article 📅 2012 🏛 CIG Media Group, LP. 🌐 English ⚖ 255 KB